Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glas… Read more
Genomic Vision Société Anonyme (G09) - Total Assets
Latest total assets as of June 2023: €3.96 Million EUR
Based on the latest financial reports, Genomic Vision Société Anonyme (G09) holds total assets worth €3.96 Million EUR as of June 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genomic Vision Société Anonyme - Total Assets Trend (2013–2022)
This chart illustrates how Genomic Vision Société Anonyme’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genomic Vision Société Anonyme - Asset Composition Analysis
Current Asset Composition (December 2022)
Genomic Vision Société Anonyme's total assets of €3.96 Million consist of 71.2% current assets and 28.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 15.2% |
| Accounts Receivable | €237.00K | 4.8% |
| Inventory | €1.39 Million | 27.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €36.00K | 0.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2013–2022)
This chart illustrates how Genomic Vision Société Anonyme's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genomic Vision Société Anonyme's current assets represent 71.2% of total assets in 2022, a decrease from 83.0% in 2013.
- Cash Position: Cash and equivalents constituted 15.2% of total assets in 2022, down from 55.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 27.9% of total assets.
Genomic Vision Société Anonyme Competitors by Total Assets
Key competitors of Genomic Vision Société Anonyme based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Genomic Vision Société Anonyme - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genomic Vision Société Anonyme generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genomic Vision Société Anonyme is currently not profitable relative to its asset base.
Genomic Vision Société Anonyme - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.41 | 1.18 | 1.47 |
| Quick Ratio | 0.36 | 0.79 | 0.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-3.36 Million | € 533.00K | € 1.49 Million |
Genomic Vision Société Anonyme - Advanced Valuation Insights
This section examines the relationship between Genomic Vision Société Anonyme's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.33 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -26.3% |
| Total Assets | €4.99 Million |
| Market Capitalization | $711.54K USD |
Valuation Analysis
Below Book Valuation: The market values Genomic Vision Société Anonyme's assets below their book value (0.14 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genomic Vision Société Anonyme's assets decreased by 26.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genomic Vision Société Anonyme (2013–2022)
The table below shows the annual total assets of Genomic Vision Société Anonyme from 2013 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | €4.99 Million | -26.32% |
| 2021-12-31 | €6.77 Million | -7.28% |
| 2020-12-31 | €7.30 Million | +30.36% |
| 2019-12-31 | €5.60 Million | -35.65% |
| 2018-12-31 | €8.71 Million | +5.15% |
| 2017-12-31 | €8.28 Million | -37.37% |
| 2016-12-31 | €13.22 Million | -39.75% |
| 2015-12-31 | €21.94 Million | -17.04% |
| 2014-12-31 | €26.44 Million | +355.85% |
| 2013-12-31 | €5.80 Million | -- |